Effects of cytochrome P450 2C9 and vitamin K epoxide reductase complex 1 genetic polymorphisms on maintenance dosage of warfarin in patients with non-valvular atrial fibrillation
Ma Jing
Huang Xiaohui
Qi Jia
Zhang Chun
Wei Xin
Abstract：Objective To investigate the effect of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex 1 (VKORC1) genetic polymorphisms on maintenance dosage of warfarin in patients with non-valvular atrial fibrillation.Methods Genotypes of CYP 2C9 and VKORC1 in 100 patients with non-valvular atrial fibrillation were detected by allele-specific real-time fluorescence polymerase chain reaction.Sex,age,weight,maintenance dose of warfarin and prothrombin time international normalized ratio were analyzed.Results Genetic test of CYP 2C9 showed 93 wild homozygotes and 7 mutant heterozygotes.Genetic test of VKORC1 showed 89 wild A/A types and 11 mutant A/G types.The maintenance dose of warfarin in CYP 2C9 mutant types was significantly less than that in wild types [(1.8 ± 0.8) mg vs (2.4 ± 1.0) mg] (P ＜ 0.01).The maintenance dose of warfarin in VKORC1 A/A types was significantly less than that in A/G types[(2.2 ± 1.0)mg vs (3.1 ± 0.8)mg] (P ＜0.01).The maintenance dose of warfarin in male was significantly less than that in female [(2.6 ± 1.2) mg vs (2.1 ±0.8)mg] (P ＜0.01).There was a decreasing trend of warfarin maintenance dose among 40-49,50-59,60-69,70-79 age groups[(2.7 ±2.5),(2.8 ±1.6),(2.4±0.9),(2.2±0.8),(2.1 ±0.9)mg].Conclusions CYP 2C9 and VKORC1 genetic polymorphisms are associated with the individual difference of warfarin maintenance dosage.Age and sex are influence factors of warfarin maintenance dosage.
Keywords：Non-valvular atrial fibrillationWarfarinGene polymorphismCytochrome P450 2C9Vitamin K epoxide reductase complex 1
Publication Date：2017-11-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1613-1616 )